Sesen Bio Inc

Sesen Bio — Investor Presentation (March 2021)

82 slides from Sesen Bio's investor presentation, Mar 1, 2021

  1. Slide 1: Corporate Deck March 1, 2021

    NASDAQ: SESN Corporate Deck March 1, 2021

  2. Slide 2: Forward-Looking Statements

    2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, clinical dev

  3. Slide 3: Business Update

    3 BUSINESS UPDATE 1. Differentiated MOA and clinical profile creates opportunity for Vicineum to be best-in-class therapeutic 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak revenue for Vi

  4. Slide 4: Our Mission Is to Save and Improve the Lives of Patients with Cancer

    O U R M I S S I O N I S TO S AV E A N D I M P ROV E T H E L I V E S O F PAT I E N T S W I T H C A N C E R BLOOD IN URINE Begin tests Cytology DIAGNOSIS BCG Testing Urologist visit UROLOGIST MAKES TREATMENT CHOICE Bladder removal See blood in urine; try different antibiotic See PCP; therapeutic trial

  5. Slide 5: 2020: A Year of Execution Excellence

    5 2020: A Year of Execution Excellence Corporate Highlights 1Q 2020 2Q 2020 3Q 2020 4Q 2020 Positive Pre-Submission meeting with EMA Completed DS PPQ campaign Favorable market research results vs. Keytruda Favorable Scientific Advice from EMA (Clinical) Received PIP waiver from EMA Signed 1st OUS de

  6. Slide 6: Significant Unmet Need for Patients with Bladder Cancer

    6 There is a Significant Unmet Need for Patients with Bladder Cancer with Limited Treatment Options Available Common Types of Cancer Estimated New Cases 2020 Estimated Deaths 2020 1. Breast Cancer (Female) 276,480 42,690 2. Lung and Bronchus Cancer 228,820 135,720 3. Prostate Cancer 191,930 33,330 4

  7. Slide 7: Vicineum Dual Mechanism of Action

    7 Vicineum has a Highly Differentiated Dual Mechanism of Action (MoA) An Important Advancement in the Category of Precision Oncology Fusion protein consisting of an antibody fragment and a cytotoxic payload Small size facilitates tumor penetration and greater drug delivery Selectively targets cancer

  8. Slide 8: Vicineum Highly Differentiated Clinical Profile

    8 Vicineum has a Highly Differentiated Clinical Profile *As referenced in FDA NMIBC Guidance for Industry, February 2018. Source: Phase III data as of the May 29, 2019 data cut. For additional information regarding Phase III clinical trial data please refer to slides 33-54. Efficacy Data Safety Data

  9. Slide 9: Partnership Opportunity with LUMC

    9 Partnership Opportunity with LUMC Further Supports the Targeting Specificity of Vicineum Gastric Cancer Colorectal Cancer Esophageal Cancer LUMC = Leiden University Medical Center, the university hospital affiliated with Leiden University. LUMC is a modern university medical center for research, e

  10. Slide 10: Favorable Cost-Effectiveness Profile Based on ICER Report

    10 Favorable Cost-Effectiveness Profile for Vicineum Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER) Overview: ICER is the leading Health Technology Assessment body in the United States, and is an independent non-profit, research organization that c

  11. Slide 11: BLA Finalized and Submitted to the FDA

    11 BLA Finalized and Submitted to the FDA on December 18, 2020 Positive Analytical Comparability Data Led to BLA Completion General corporate information Patent information and exclusivity Waivers Draft Label Risk management plan Draft carton and container labels 24 Non-clinical studies 30 Non-clini

  12. Slide 12: Completion of Vicineum BLA Submission in December 2020

    12 Completion of Vicineum BLA Submission in December 2020 Sources: FDA applications for oncolo et al., Clinical development success rates 2006-2015. 2016. Bio, BioMedTracker and Amplion. Phase Probability of Approval Products at end of Phase I 5% Products at end of Phase II 8% Products at end of Pha

  13. Slide 13: Forward-looking Timeline for Vicineum

    13 4Q 20 1Q 21 2Q 21 3Q 21 4Q 21 2Q 221Q 22 Positive progress in the US and Europe enables a clear regulatory path forward with the following anticipated milestones: BLA completion BLA approval BLA=Biologics License Application; MAA=Marketing Authorization Application; HTA=Health Technology Assessme

  14. Slide 14: Substantial US Opportunity and OUS Potential

    14 Substantial US opportunity and OUS potential of roughly two times the US Anticipated virtuous cycle of advocacy across physicians, patients/caregivers, and payers to drive rapid uptake and strong growth after approval and launch Compelling intent to prescribe research in the US Highly concentrate

  15. Slide 15: Key Partnership with Hikma in MENA

    15 Key partnership with leading partner in MENA Hikma Pharmaceuticals Profile Multi-national pharma company specializing in the development and commercialization of a broad range of high-quality medicines across the US, MENA and Europe Public company headquartered in London with a market cap of >$6B

  16. Slide 16: Milestones Achieved through Qilu Partnership

    16 Significant Milestones Achieved through Qilu Pharmaceutical Partnership Overview of Key Progress $12M upfront received on September 29, 2020 CMO framework agreement signed on December 4, 2020 Helps to ensure reliable global supply and creates opportunity for a reduction in COGS $3M milestone expe

  17. Slide 17: OUS Opportunity Roughly Double the US

    17 We Estimate the OUS Opportunity for Vicineum is Roughly Double the US Geography Peak Year Revenue Opportunity for Vicineum (captures 80% of variance) Europe $450M - $1,125M United States* $423M - $942M MENA $158M - $420M China $155M - $418M Rest of Asia (incl. Japan) $109M - $282M Latin America $

  18. Slide 18: 2020 Financial Highlights

    18 2020 Financial Highlights Strengthening the Balance Sheet while Minimizing Dilution YE 2019 YE 2020 % Change Cash, cash equivalents and restricted cash $48M $55M1 +15% Stock price $1.04 $1.35 +30% Market cap $111M $190M +71% 1Amount is preliminary, has not been audited and is subject to nts for t

  19. Slide 19: Sesen Bio Highlights

    19 SESEN BIO HIGHLIGHTS 1. Differentiated MOA and clinical profile creates opportunity for Vicineum to be best-in-class therapeutic 2. Clear regulatory path forward for potential approval in US in 2021 and Europe in 2022 3. Significant global commercial opportunity; projected $1B - $3B peak revenue

  20. Slide 20: Thank You

    THANK YOU

  21. Slide 21: Talented and Experienced Leadership Team

    21 Thomas Cannell, DVM President, CEO and Director Glen MacDonald, Ph.D. Chief Technology Officer Mark Sullivan General Counsel and Corporate Secretary Erin Clark Vice President, Corporate Strategy and Investor Relations Monica Forbes Chief Financial Officer Omar Rifi Vice President, Business Develo

  22. Slide 22: Appendix - Table of Contents

    22 Appendix - Table of Contents Section Slide number Unmet Medical Need 23-26 Dual Mechanism of Action 27-29 Regulatory 30-32 Clinical Data 33-54 Commercial Opportunity 55-74 Manufacturing & Supply Chain 75-80 Intellectual Property 81-82 For Investor Purposes Only

  23. Slide 23: Unmet Medical Need

    23 Unmet Medical Need Appendix

  24. Slide 24: Significant Unmet Medical Need in NMIBC

    24 BCG ~440,000 new cases each year globally1 is complicating patient care Significant Unmet Medical Need in NMIBC 1Bray F et al. CA Cancer J Clin, 2018. 2Anastasiadis et al. Therapeutic Advances in Urology, 2012. 3Siegel et al. CA Cancer J Clin, 2019. 4Svatek RS, et al. Eur Oncol. 2014. 5Office of

  25. Slide 25: Vicineum Is Bladder-Sparing by Delaying or Avoiding Cystectomy

    25 Our Phase III data suggests Vicineum is bladder-sparing by significantly delaying or avoiding cystectomy for patients Your Bladder: An Essential Organ Radical Cystectomy: Life-Altering Surgery Self-controlled storage organ in the body Holds urine for release so the body is not exposed to harmful

  26. Slide 26: NMIBC Therapeutics Plagued by Manufacturing Issues

    26 NMIBC Therapeutics Have Been Plagued by Manufacturing Issues 2012 2013 2014 2015 2016 2017 2018 2019 2020 Sanofi suspends production of BCG Connaught strain during facility renovations Merck announces shortages of BCG Tice strain Sanofi discontinues all global production of BCG Connaught strain M

  27. Slide 27: Dual Mechanism of Action

    27 Dual Mechanism of Action Appendix

  28. Slide 28: Vicineum Highly Differentiated Mechanism of Action

    28 T cells recognize neoantigen and kill cancer cells T cell proliferation DAMPs Neoantigen release Vicineum causes immunogenic cell death by triggering damage-associated molecular patterns (DAMPs) Vicineum selectively targets EpCAM on cancer cells while generally leaving healthy cells alone Vicineu

  29. Slide 29: Immunogenic Cell Death Evidence

    29 A f t e r 4 w k s o n t r e a t m e n t P r e - t r e a t m e n t PAT I E N T A : PAT I E N T B : Injected Tumor Injected Tumor Non-Injected Tumor Pre-clinical and Phase I Trial in SCCHN sh immune systems Clinical Evidence (as seen in Phase I) Pre-Clinical Evidence Immunogenic Cell Death (ICD) Pr

  30. Slide 30: Regulatory

    30 Regulatory Appendix

  31. Slide 31: 2018 FDA Guidance and Vicineum Clinical Program

    31Source: FDA Guidance: BCG-Unresponsive Non-muscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, February 2018. CRR, Complete Response Rate; DoR, Duration of Response; BCG, bacillus Calmette-Guérin; WHO, World Health Organization. 31 ss toxicity in ani

  32. Slide 32: Positive Interactions with EMA on Regulatory Pathway

    32 Positive Interactions with EMA on Regulatory Pathway for Vicineum May 7, 2020 CHMP clinical advice for Vicineum: The nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a MAA submission for Vicineum and no additional clinical trials were requested Ther

  33. Slide 33: Clinical Data

    33 Clinical Data Appendix

  34. Slide 34: Strong Benefit-Risk Profile in Phase III Trial

    34 : Vicineum demonstrates a strong benefit-risk profile in our Phase III Trial Benefit Risk Safety and Tolerability Selectively targets cancer cells while generally avoiding healthy cells Favorable profile relative to BCG, Valstar, checkpoint inhibitors No dose or age-related increase in AEs Intrav

  35. Slide 35: Phase III Trial: Patient Demographics

    35 Phase III Trial: Patient Demographics TURBT: transurethral resection of bladder tumor Note: Data are as of May 29, 2019 data cut CHARACTERISTICS COHORT 1 COHORT 2 COHORT 3 CIS that was refractory or recurred within 6 months of adequate BCG CIS that recurred >6 months but 11 months of adequate BCG

  36. Slide 36: Compelling Clinical Data Set

    36 Compelling Clinical Data Set Endpoint How Endpoint is Measured Results Complete Response Rate (CRR) Primary Endpoint CIS patients Defined as the proportion of patients who show no evidence of high-risk disease, or disease progression (e.g., T2 or more advanced disease). 40% CRR at 3 months Lower

  37. Slide 37: Complete and Partial Response in Phase II

    37 Complete and Partial Response: In our Phase II clinical trial, 83% of patients had a complete or partial response Start of Treatment with Vicineum 3-Month Response 40% of patients had a complete response 43% of patients had a partial response 17% of patients had no response *Note: Data are from P

  38. Slide 38: Duration of Response

    38 Duration of response: defined as the time of complete response to treatment failure. *Not Estimable, the upper bound for the 95% confidence interval has not reached the median. **Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Median duration of response for th

  39. Slide 39: Duration of Response by BCG Exposure

    39 Duration of Response: Vicineum is generally more efficacious in CIS patients treated with less BCG Duration of response: defined as the time of complete response to treatment failure. *Note: Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. The BCG shortage may cause a

  40. Slide 40: Probability of Maintaining Complete Response

    40Duration of response: defined as the time from complete response to treatment failure. *Data reflect an ad hoc analysis of pooled results of patients in cohorts 1&2. Duration of Response: The longer you have a complete response, the higher the probability of remaining cancer-free 17% 42% 56% 61% 7

  41. Slide 41: Time to Disease Recurrence

    41 Time to Disease Recurrence: Time to Disease Recurrence: 50% of high-risk papillary patients who were treated with Vicineum are disease-free at 1 year Time to disease recurrence: defined as the time from the date of the first dose of study treatment to treatment failure. Median time to disease rec

  42. Slide 42: Time to Cystectomy Data vs. Available Agents

    42 2018 FDA Guidance: The goal of therapy in patients with BCG-unresponsive NMIBC is to avoid cystectomy. % o f Pa ti en ts C ys te ct o m y- Fr ee Median 3 6 9 12 15 18 21 240 27 30 33 Time from start of treatment (months) KM Estimate Censored 95% CI X Legend: No patient on treatment progressed to

  43. Slide 43: Time to Cystectomy: Responders

    43 Time to Cystectomy: Responders have an 88% probability of remaining cystectomy-free 3 years after starting treatment Time to cystectomy: defined as the time from the date of first dose of study treatment to surgical bladder removal. Data consist of patients from all cohorts (n=133). % o f Pa ti e

  44. Slide 44: Overall Survival

    44 Overall Survival 1- and 2-year survival rates of patients on trial are comparable to those of the general population of similar age and gender demographics (predominantly male in their 70s) 1U.S. Social Security Administration Actuarial Life Table (https://www.ssa.gov/oact/STATS/table4c6.html), B

  45. Slide 45: Additional Vicineum Clinical Data: Phase II vs. Phase III

    45 Additional Vicineum Clinical Data Preliminary Phase II vs. Phase III Complete Response Rate Time Point Phase II Pooled CRR (95% Confidence Interval) Phase III Pooled CRR (95% Confidence Interval) 3 months 40% (26% 56%) 40% (30% 51%) 6 months 27% (15% 42%) 28% (19% 39%) 9 months 18% (8% 32%) 21% (

  46. Slide 46: Evaluable Patient Data Tables for Carcinoma in Situ

    46 Phase III Trial: Evaluable Patient Data Tables by Cohort for Carcinoma in situ Cohort 1 (n=82) Complete Response Rate Time Point Evaluable Patients Complete Response Rate (95% Confidence Interval) 3 months n=82 39% (28% 50%) 6 months n=82 26% (17% 36%) 9 months n=82 20% (12% 30%) 12 months n=82 1

  47. Slide 47: Recurrence-free Rate in Papillary Patients

    47 Recurrence-free Rate: 42% of high-risk papillary patients remain disease- free after one year Recurrence free (RF) Rate (Papillary patients) Time Point Evaluable Patients RF Rate (95% Confidence Interval) 3 months n=38 71% (54% 85%) 6 months n=38 58% (41% 74%) 9 months n=38 45% (29% 62%) 12 month

  48. Slide 48: Safety and Tolerability: Phase II and III

    48 Safety and Tolerability: Our Phase II and Phase III clinical trials are highly consistent for safety and tolerability Category Phase II Patients (%) Phase III Patients (%) Any AE 43 (94%) 117 (88%) Grade 3-5 AEs 9 (20%) 29 (22%) Treatment-related AEs 30 (65%) 66 (50%) Treatment-related Grade 3-5

  49. Slide 49: No Age-Related Increase in Adverse Events

    49 0 2 4 6 8 10 Safety and Tolerability: No age-related increase in adverse events in our Phase III trial Note: Data consist of patients from all cohorts (n=133). Mean AEs for all patients: 8.1 (range 0-54), Mean treatment-related AEs for all patients: 2.2 (range 0-51). Adverse Events Treatment-rela

  50. Slide 50: Confidence Interval Above FDA Success Criterion

    50 Vicineum confidence interval above FDA success criterion based upon complete response of other agents in patients with Carcinoma in situ Please use caution when drawing comparisons across different clinical trials 2Data are as of May 29, 2019 data cut from the Phase III VISTA trial 3To demonstrat

  51. Slide 51: Overview of Planned Confirmatory Trial

    51 High-Level Overview of Planned Confirmatory Trial Successful in alignment with the FDA on the design of the post-marketing confirmatory trial for Vicineum Key Elements The confirmatory trial will enroll BCG-refractory patients who received less-than-adequate BCG* This represents a broader patient

  52. Slide 52: Head and Neck Cancer: Difficult-to-Treat

    HEAD AND NECK CANCER: Difficult-to-Treat & Dominated by Primary Tumor Head and neck cancer affects >650,000 people worldwide; ~350,000 deaths each year1 90% are squamous cell carcinomas of the head and neck (SCCHN)1 - Two-thirds diagnosed with advanced disease and severe prognosis High risk of recur

  53. Slide 53: Monotherapy Studies in Late-stage SCCHN

    53 PHASE 1 TRIALS ASSESSING DAILY AND WEEKLY DOSES SUGGEST IMMUNE-DRIVEN RESPONSE Anti-tumor activity of 43% on daily dose; 62% on weekly dose Observed regression or complete resolution of non- injected tumors 207 days mean overall survival for EpCAM-positive patients vs. 125 days for EpCAM-negative

  54. Slide 54: Pipeline of Targeted Therapies

    54 Pipeline of Targeted Therapies We believe there is strong scientific rationale for Vicineum in combination with checkpoint inhibitors. Vicineum in mab), is being evaluated in a Phase 1 trial run by the National Cancer Institute. We have deferred further development of Vicineum, for the treatment

  55. Slide 55: Commercial Opportunity

    55 Commercial Opportunity Appendix

  56. Slide 56: Virtuous Cycle: Physicians, Patients and Payers

    56 Virtuous Cycle: High possibility that all three key segments are advocates & take action Sources: Sesen Bio internal market research: Patient Journey Insights, Blue Print qualitative study May 2018, n=24; Sesen Market Opportunity, Monitor Deloitte qualitative and quantitative (n=34) study October

  57. Slide 57: Differentiated vs. Branded Agents in Urology

    57 Brand Logo Differentiated vs. branded agents in Urology TM

  58. Slide 58: Treatment Protocol Comparison

    58 Treatment Protocol BCG Vicineum Checkpoint Inhibitors Treatment at Urology office X Directed by Urologist X Administration by Urology nurse X Bladder infusion via urinary catheter X 2-hour infusion, hold, and rotation X Vicineum has the Potential to Provide Continuity of Care for Patients with NM

  59. Slide 59: Clinical Data from Emerging Treatments for NMIBC

    59 Gen Vicineum Profile (Phase III Data) Keytruda Profile (Phase II Data) Tecentriq Profile (Phase II Data) Efficacy N=89 N=102 N=73 Complete Response Rate At 3 Months At 12 Months At 18 Months 40% (CI: 30-51) 17% 15% 41% (CI: 32-51) 20% 13% 41% (CI: 30-53) No data reported No data reported Time to

  60. Slide 60: 2020 Market Research: Urologists Prefer Vicineum Profile

    60 5.4 8.2 8.2 8.6 5.2 6.2 3.4 5.8 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0 Efficacy Safety Ease of integration Interest in use of product A ve ra ge R at in g Vicineum Profile Keytruda Profile 2020 Market Research Results High Prescribing Urologists Prefer Vicineum Profile Source: Emerging trea

  61. Slide 61: Reasons Urologists Prefer Vicineum Profile

    61 1Q 2020 Market Research Results Reasons Urologists Prefer Vicineum Profile Urologists strongly prefer to retain ownership of patient journey Urologists perceive favorable product profile for Vicineum olerability relative to Keytruda profile Urologists perceive administration of Vicineum as highly

  62. Slide 62: Concentrated Prescriber Base Allows Efficient Commercial Model

    62 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 20 0 40 0 60 0 80 0 1, 00 0 1, 20 0 1, 40 0 1, 60 0 1, 80 0 2, 00 0 2, 20 0 2, 40 0 2, 60 0 2, 80 0 3, 00 0 3, 20 0 3, 40 0 3, 60 0 3, 80 0 4, 00 0 4, 20 0 4, 40 0 4, 60 0 4, 80 0 BCG Prescribers Highly Concentrated Prescriber Base Allows for Efficien

  63. Slide 63: Caregiver Education via Digital and Social Channels

    63 At treatment decision points, caregivers often play an influential role Our strategy is to educate and inform caregivers via a wide range of digital and social channels Digital Paid search Organic search Videos Banners Website (branded or unbranded) Social Facebook community groups Twitter Lead g

  64. Slide 64: Pricing and Reimbursement

    64 Pricing and Reimbursement US Benchmarks Price Reference (Annual Cost) $200K $0K Sources: 1Center for Medicare and Medicaid Services (CMS) Average Selling Price (ASP) Price List as of 1Q 2020 (cms.gov). 2Payer Interviews, ClearView Analysis, n=10, March 2019. *Note: Payers cited a possibility of u

  65. Slide 65: Competitive Landscape: Checkpoint Inhibitors and Gene Therapy

    65 Checkpoint Inhibitors: Keytruda Approved for NMIBC January 2020 Reimbursed at $175,000/year with minimal payer restrictions Tecentriq Awaiting Phase III enrollment Phase II closed prematurely as it failed to meet futility endpoint Gene Therapy: Adenovirus Vectors Adstiladrin3 Missed May PDUFA dat

  66. Slide 66: Competitive Summary: BCG-Unresponsive NMIBC Therapies

    66 Competitive Summary: BCG-Unresponsive NMIBC therapies Report CR rate at discrete timepoints Patient failures taken off therapy Local and Central review of pathology BCG + N-803 BCG in combo with rIL-15 Vicineum Fusion Protein (Dual MOA) Keytruda Checkpoint Inhibitor Adstiladrin Gene Therapy Treat

  67. Slide 67: Sesen Bio OUS Strategy Overview

    67 Sesen Bio OUS Strategy Overview Vicineum is a product with potential for registration and reimbursement in multiple developed markets OUS opportunity for Vicineum is 2-3 times larger than the US Efficient process to manage strong, engaged relationships with key partners worldwide Partner with 6-1

  68. Slide 68: Sesen Bio OUS Update

    68 Sesen Bio OUS Update July 31, 2020: Announced partnership with Qilu Pharmaceutical for the manufacture, development and commercialization of Vicineum in Greater China* Represents the first of 6-10 anticipated OUS deals Financial terms include significant sources of non-dilutive capital Qilu will

  69. Slide 69: Partnership Opportunity in China: Qilu Pharmaceutical

    69 Partnership Opportunity in China: Qilu Pharmaceutical Profile Top 10 Pharmaceutical Company in China with >$3B in annual revenue Extensive clinical experience 2nd largest clinical team in Chinese Big Pharma Focused on biosimilar and innovative drugs, with nearly 40 years of clinical development e

  70. Slide 70: Overview of Qilu License Agreement

    70 Overview of Qilu License Agreement Financial terms include significant sources of non-dilutive capital Upfront payment of $12M in cash Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to 12% royalties on net sales for at least 12 years Qilu will be the Mark

  71. Slide 71: Building Our Reputation as a Partner of Choice

    71 Strong cultural fit between Sesen and Qilu Significant CMC capabilities and experience Highly knowledgeable clinical and manufacturing teams Vicineum is a highly differentiated product that addresses a huge unmet need Building Our Reputation as a Partner of Choice Feedback Received from Qilu Duri

  72. Slide 72: Forecast Simulation Model Key Assumptions

    72 Forecast Simulation Model Key Assumptions US and OUS High-risk NMIBC patients unresponsive to BCG Estimated peak market share Approximate year 1 doses received Anticipated annual CMS ASP Prevalence (relative to US) Price (relative to US) US Inputs OUS Inputs Output Peak Revenue Opportunity for Vi

  73. Slide 73: Simulation Inputs: US Market

    73 Simulation Inputs: US Market Estimated patients eligible for branded therapy1 (Annual high-risk NMIBC patients unresponsive to BCG) Lower Bound 7,800 patients Upper Bound 20,400 patients Estimated peak market share2 (Likely share of branded agents) Approximate year 1 doses received3 (Percent of p

  74. Slide 74: Simulation Inputs: OUS Market

    74 Simulation Inputs: OUS Market Sources: Ferlay. Intern. J. Canc. 2015; UN World Population Reports; SEER; GLOBOCAN; RedBook; Lauertaxe; Ameli; NICE; Vademecum; AIFA; NHI; CADTH; ANVISA; CBiP; Danish Medicines Agency; The Pharmaceutical Benefits Scheme; Saudi Food & Drug Authority; South African Me

  75. Slide 75: Manufacturing & Supply Chain

    75 Manufacturing & Supply Chain Appendix

  76. Slide 76: Vicineum End-to-End Supply Chain

    76 Vicineum End-to-End Supply Chain World-class manufacturing and distribution capabilities ensure execution excellence Vicineum Drug Substance manufacturer 7 commercial products launched from site where Vicineum is manufactured o 3 produced via E. coli o 2 oncology products 30+ years manufacturing

  77. Slide 77: Highly Reliable Manufacturing Process for Vicineum

    77 Highly Reliable Manufacturing Process for Vicineum Cell Bank 2000 L E. coli Production Bioreactor 5: Q-Sepharose HP 5 Column Purification Shake flask Centrifugation (bulk solids removal) Clarification (MF for fine solids removal and UF/DF for buffer exchange) DP Fill Finish (7 mL @ 5mg/mL) 1: Q-S

  78. Slide 78: Reliable and Inexpensive Manufacturing Process

    78 Reliable and Inexpensive Manufacturing Process Vicineum is manufactured using a robust, industry-standard microbial expression system The manufacturing process is highly reliable, reducing the risk of supply shortages The manufacturing process is inexpensive, leading to a relatively low cost-of-g

  79. Slide 79: Commercial Manufacturing Strategy Based on Comparability

    79 Commercial Manufacturing Strategy Based on Demonstrating Comparability The analytical comparability plan is comprised of 4 key elements: 1. Analytical Release Testing Assesses the purity, biological activity and general characteristics of Vicineum 2. Biophysical Characterization Assesses the stru

  80. Slide 80: Meaningful Progress on Demonstrating Comparability

    80 Meaningful Progress on Demonstrating Comparability Indicates acceptance criteria met for batches used in clinical trials (Sesen) or technology transfer (FUJIFILM Diosynth Biotechnologies) Sesen FUJIFILM Diosynth Biotechnologies Test Phase III PPQ1 PPQ2 PPQ3 Appearance pH Identity Concentration Po

  81. Slide 81: Intellectual Property

    81 Intellectual Property Appendix

  82. Slide 82: Patent Life and Biologics Marketing Exclusivity

    82 Potential for 12 years of biologics marketing exclusivity from date (TBD) of first approval* Stabilized Chimeric Immunoglobulins (April 2020 - July 2020) 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Methods of Treating Cancer Using an Immunotoxin (April 202

Sesen Bio — Investor Presentation (March 2021) on 6ix